Rheopheresis in patients with ischemic diabetic foot syndrome: Results of an open label prospective pilot trial

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 444-455

  Klingel, Reinhard ^a   Mumme, Christian ^d   Fassbender, Thurid ^a   Himmelsbach, Frido ^b   Altes, Ulrich ^b   Lotz, Johannes ^d   Pohlmann, Thomas ^c   Beyer, Jürgen ^d   Küstner, Ernst ^d  

^a Apheresis Research Institute   (Germany)

^b Center for Dialysis and Apheresis   (Germany)

^c Institute for Clinical Research and Development   (Germany)

^d NONE

Author keywords

2 macroglobulin; Fibrinogen; Ischemic diabetic foot syndrome; LDL cholesterol; Microcirculation; Rheopheresis; Transcutaneous oxygen tension; Wound healing

Indexed keywords

ADULT; AGED; BLOOD RHEOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENDOTHELIUM CELL; EXTRACORPOREAL OXYGENATION; FEMALE; FOOT AMPUTATION; FOOT ULCER; FUNCTIONAL ASSESSMENT; HUMAN; ISCHEMIC DIABETIC FOOT SYNDROME; LASER DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN TENSION; PARAMETER; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEOPHERESIS; SAFETY; SKIN BLOOD FLOW; TREATMENT OUTCOME; WOUND HEALING;

AGED; DIABETIC FOOT; FEMALE; FOLLOW-UP STUDIES; FOOT; HEMOFILTRATION; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMAPHERESIS; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR PATENCY; WOUND HEALING;

EID: 0041315451     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00082.x     Document Type: Review

References (39)

1. Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996;13:967-72.
2. Schömig M, Ritz E, Standl E, Allenberg J. The diabetic foot in the dialyzed patient. J Am Soc Nephrol 2000;11:1153-9.
3. Reiber GE, Boyko WJ, Smith DG. Lower extremity foot ulcers and amputations in individuals with diabetes. In: Harris, MI, Cowrie, CC, Stern, MP, eds. Diabetes in America. DHHS Publication no. 95-1468, Washington, DC. U.S. Government Printing Office 1995.
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis, epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
5. Mayrovitz HN, Larsen PB. Functional microcirculatory impairment: a possible source of reduced skin oxygen tension in human diabetes mellitus. Microvasc Res 1996;52:115-26.
6. Zimny S, Dessel F, Ehren M, Pfohl M, Schatz H. Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001;24:1810-4.
7. Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 1991;40:1305-13.
8. Le Devehat C, Khodabandehlou T. Transcutaneous oxygen pressure and hemorheology in diabetes mellitus. Int Angiol 1990;9:259-62.
9. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. J Vasc Surg 1995;22:485-92.
10. 2 as an accurate predictor of therapy in limb salvage. Ann Vasc Surg 1996;10:224-7.
11. Klingel R, Fassbender C, Fassbender T, Erdtracht B, Berrouschot J. Rheopheresis: Rheologic, functional, and structural aspects. Ther Apher 2000;4:348-57.
12. Blann A, Bignell A, McCollum C. von Willebrand factor, fibrinogen, and other plasma proteins as determinants of plasma viscosity. Atherosclerosis 1998;139:317-22.
13. Ganda OP, Arkin CF. Hyperfibrinogenemia - an important risk factor for vascular complications in diabetes. Diabetes Care 1992;15:1245-50.
14. Jaeger BR. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostatsis. Ther Apher 2001;5:207-11.
15. Solerte SB, Fioravanti M, Ferrari E. Plasma fibronectin as an indicator of microvascular damage in diabetic patients. Rapid and sensitive evaluation by a radial immunodiffusion technique. Ric Clin Laboratory 1987;17:251-8.
16. Klingel R, Pulido J, Fassbender C et al. Rheopheresis for age-related macular degeneration - a novel indication for therapeutic apheresis in ophthalmology. Therapeutic Apheresis 2002;6:271-81.
17. Brunner R, Widder RA, Walter P et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration. A randomized trial. Retina 2000;20:483-91.
18. Lüke C, Widder RA, Soudavar F, Walter P, Brunner R, Borberg H. Improvement of macular function by membrane differential filtration in diabetic retinopathy. J Clin Apheresis 2001;16:23-8.
19. Wagner FW. The dysvascular foot. a system for diagnosis and treatment. Foot Ankle 1981;2:64-122.
20. Belcaro G, Vasdekis S, Rulo A, Nicolaides AN. Evaluation of blood flow and venoarteriolar response in patients with diabetes and peripheral vascular disease by laser-Doppler flowmetry. Angiology 1989;40:953-7.
21. Boyko EJ, Ahroni JH, Stensel VL. Tissue oxygenation and skin blood flow in the diabetic foot: responses to cutaneous warming. Foot Ankle Int 2001;22:711-4.
22. Lawall H, Amann B, Rottmann M, Angelkort B. The role of microcirculatory techniques in patients with diabetic foot syndrome. VASA 2000;29:191-7.
23. Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJM. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med 2002;13:185-9.
24. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Serum concentration of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Prac 2002;55:131-8.
25. Ridker PM. High-sensitivity C-reactive protein. Circulation 2001;103:1813-8.
26. Sprenger KB, Huber K, Kratz W, Henze E. Nomograms for the prediction of patient's plasma Volume in plasma exchange therapy from height, weight, and hematocrit. J Clin Apheresis 1987;3:185-90.
27. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998;21:855-9.
28. Lübbers DW. Cutaneous and transcutaneous pO2 and pCO2 and their measuring conditions. In: Huch A, Huch R, Lucea JF, eds. Continuous Transcutaneous Blood Gas Monitoring, Original Article Series-Birth Defects. New York: The National Foundation March of Dimes, 1979;13-31.
29. Karanfilian RG, Lynch TG, Zirul VT, Padberg FT, Zafir J, Hobson RW. The value of laser Doppler velocimetry and transcutaneous oxygen tension determination in predicting healing of ischemic forefoot ulcerations and amputations in diabetic and nondiabetic patients, J Vasc Surg 1986;4:511-6.
30. Brun JF. Hormones, metabolism and body composition as major determinants of blood rheology: Potential pathophysiological meaning. Clin Hemorheol Microcirculation 2002;26:63-79.
31. Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot, Diabetes Metab Res Rev 2000;16:S55-8.
32. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygeb (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002;16:153-8.
33. Fagrell B, Hermansson JL, Karlander JG, Oestergreen J. Vital capillary microscopy for assessment of skin viability and microangiopathy in patients with diabetes mellitus. Act Med Scand 1984;687:25-8.
34. Aso Y, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Elevation of von Willebrand factor in plasma in diabetic patients with neuropathic foot ulceration. Diabetic Med 2002;19:19-26.
35. Ridker PM, Hennekens CH, Buring JE, Rifai N. C reactive protein and other markers of inflammation in the predictive of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
36. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998;111:850-7.
37. Skrha J, Vackova I, Kvasnicka J et al. Plasma free N-terminal fibronectin 30-kDa domain as a marker of endothelial dysfunction in type 1 diabetes mellitus. Eur J Clin Invest 1990;20:171-6.
38. Solerte SB, Piovella F, Viola C et al. Plasma fibronectin, von Willebrand factor antigen, and blood rheology. Association with diabetic microvascular disease. Acta Diabetol Lat 1985;22:239-46.
39. Richter WO, Schneidewind JM, Ramlow W et al. Extracorporeal fibrinogen adsorption-efficacy, selectivity and safety in healthy subjects and patients with foot ulcers. Transfusion Apheresis Sci 2002;26:15-27.